Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model

Neuro-Oncology

Volumn 18, Issue 12, 2016, Pages 1622-1633

  Okolie, Onyinyechukwu ^a   Bago, Juli R ^a   Schmid, Ralf S ^c   Irvin, David M ^c   Bash, Ryan E ^c   Miller, C Ryan ^b,c   Hingtgen, Shawn D ^a,b,c  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Glioblastoma; Glioma; Migration; Reactive astrocytosis; Recurrence

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; TRANSCRIPTOME;

ALLOGRAFT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL CULTURE; COCULTURE; CONTROLLED STUDY; FLUORESCENCE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGE GUIDED BIOPSY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METASTASIS; MICROGLIA; MICROSURGERY; MOUSE; NEUROSURGERY; NONHUMAN; RNA SEQUENCE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE; TUMOR VOLUME; ANIMAL; BRAIN TUMOR; CELL MOTION; CELL PROLIFERATION; DISEASE MODEL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ALLOGRAFTS; ANIMALS; ASTROCYTES; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; GLIOBLASTOMA; MICE; NEOPLASM RECURRENCE, LOCAL; TRANSCRIPTOME; TUMOR MICROENVIRONMENT;

EID: 85017614562     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now117     Document Type: Article

References (58)

1. Ehtesham M, Kabos P, Gutierrez MA, et al. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A. 2000;97(23): 12846–12851.
2. Adamson C, Kanu OO, Mehta AI, et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs. 2009;18(8):1061–1083.
3. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492–507.
4. Hou LC, Veeravagu A, Hsu AR, et al. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus. 2006;20(4):E5.
5. Minniti G, De Sanctis V, Muni R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol. 2008;88(1):97–103.
6. Nieder C, Grosu AL, Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev. 2000;26(6): 397–409.
7. Tejada S, Aldave G, Marigil M, et al. Factors associated with a higher rate of distant failure after primary treatment for glioblastoma. J Neurooncol. 2014;116(1):169–175.
8. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res. 1979;39(10): 3861–3865.
9. Hingtgen S, Figueiredo JL, Farrar C, et al. Real-time multi-modality imaging of glioblastoma tumor resection and recurrence. J Neurooncol. 2013;111(2):153–161.
10. Kauer TM, Figueiredo JL, Hingtgen S, et al. Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat Neurosci. 2012;15(2):197–204.
11. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190–198.
12. McNeill RS, Vitucci M, Wu J, et al. Contemporary murine models in preclinical astrocytoma drug development. Neuro Oncol. 2015; 17(1):12–28.
13. Hoelzinger DB, Demuth T, Berens ME. Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst. 2007;99(21):1583–1593.
14. Charles NA, Holland EC, Gilbertson R, et al. The brain tumor microenvironment. Glia. 2011;59(8):1169–1180.
15. Shiao SL, Ganesan AP, Rugo HS, et al. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev. 2011;25(24): 2559–2572.
16. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
17. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467): 346 – 354.
18. Huszthy PC, Daphu I, Niclou SP, et al. In vivo models of primary brain tumors: pitfalls and perspectives. Neuro Oncol. 2012;14(8):979–993.
19. Song Y, Zhang Q, Kutlu B, et al. Evolutionary etiology of high-grade astrocytomas. Proc Natl Acad Sci U S A. 2013;110(44):17933–17938.
20. McNeill RS, Schmid RS, Bash RE, et al. Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice. J Vis Exp. 2014;(90):e51763.
21. Vitucci M, Karpinich NO, Bash RE, et al. Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis. Neuro Oncol. 2013;15(10):1317–1329.
22. Bago JR, Alfonso-Pecchio A, Okolie O, et al. Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma. Nat Commun. 2016;7:10593.
23. Irvin DM, McNeill RS, Bash RE, et al. Intrinsic astrocyte heterogeneity influences tumor growth in glioma mouse models. Brain Pathol. 2016:10.1111/bpa.12348.
24. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550.
25. Schmid RS, Simon JM, Vitucci M, et al. Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide. Neuro Oncol. 2016: doi: 10.1093/neuonc/nov321.
26. Hess KR. Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol. 1999;42(3):227–231.
27. Affronti ML, Heery CR, Herndon JE 2nd, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 2009;115(15):3501–3511.
28. Katz AM, Amankulor NM, Pitter K, et al. Astrocyte-specific expression patterns associated with the PDGF-induced glioma microenvironment. PLoS One. 2012;7(2):e32453.
29. Liu L, Wu J, Ying Z, et al. Astrocyte elevated gene-1 upregulates matrix metalloproteinase-9 and induces human glioma invasion. Cancer Res. 2010;70(9):3750–3759.
30. Le DM, Besson A, Fogg DK, et al. Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade. J Neurosci. 2003;23(10):4034–4043.
31. Hong X, Sin WC, Harris AL, et al. Gap junctions modulate glioma invasion by direct transfer of microRNA. Oncotarget. 2015;6(17): 15566–15577.
32. Rhodes KE, Moon LD, Fawcett JW. Inhibiting cell proliferation during formation of the glial scar: effects on axon regeneration in the CNS. Neuroscience. 2003;120(1):41–56.
33. Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci. 2004;5(2):146–156.
34. Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009;32(12):638–647.
35. Robel S, Berninger B, Gotz M. The stem cell potential of glia: lessons from reactive gliosis. Nat Rev Neurosci. 2011;12(2):88–104.
36. Okada S, Nakamura M, Katoh H, et al. Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat Med. 2006;12(7):829–834.
37. Buffo A, Rite I, Tripathi P, et al. Origin and progeny of reactive gliosis: a source of multipotent cells in the injured brain. Proc Natl Acad Sci U S A. 2008;105(9):3581–3586.
38. Shimada IS, LeComte MD, Granger JC, et al. Self-renewal and differentiation of reactive astrocyte-derived neural stem/ progenitor cells isolated from the cortical peri-infarct area after stroke. J Neurosci. 2012;32(23):7926–7940.
39. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):7–35.
40. Yang C, Iyer RR, Yu AC, et al. Beta-catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas. Proc Natl Acad Sci U S A. 2012; 109(18):6963–6968.
41. Feng GD, He BR, Lu F, et al. Fibroblast growth factor 4 is required but not sufficient for the astrocyte dedifferentiation. Mol Neurobiol. 2014;50(3):997–1012.
42. Gao K, Wang CR, Jiang F, et al. Traumatic scratch injury in astrocytes triggers calcium influx to activate the JNK/c-Jun/AP-1 pathway and switch on GFAP expression. Glia. 2013;61(12): 2063–2077.
43. Yong RL, Yang C, Lu J, et al. Cell transcriptional state alters genomic patterns of DNA double-strand break repair in human astrocytes. Nat Commun. 2014;5:5799.
44. Nagashima G, Suzuki R, Asai J, et al. Immunohistochemical analysis of reactive astrocytes around glioblastoma: an immunohistochemical study of postmortem glioblastoma cases. Clin Neurol Neurosurg. 2002;104(2):125–131.
45. Faulkner JR, Herrmann JE, Woo MJ, et al. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci. 2004;24(9):2143–2155.
46. Myer DJ, Gurkoff GG, Lee SM, et al. Essential protective roles of reactive astrocytes in traumatic brain injury. Brain. 2006;129(Pt 10):2761–2772.
47. Sofroniew MV. Reactive astrocytes in neural repair and protection. Neuroscientist. 2005;11(5):400–407.
48. Barbero S, Bonavia R, Bajetto A, et al. Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res. 2003;63(8):1969–1974.
49. Yang C, Rahimpour S, Yu AC, et al. Regulation and dysregulation of astrocyte activation and implications in tumor formation. Cell Mol Life Sci. 2013;70(22):4201–4211.
50. Yang H, Feng GD, Olivera C, et al. Sonic hedgehog released from scratch-injured astrocytes is a key signal necessary but not sufficient for the astrocyte de-differentiation. Stem Cell Res. 2012;9(2):156–166.
51. Hussain SF, Yang D, Suki D, et al. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006;8(3):261–279.
52. Raposo C, Schwartz M. Glial scar and immune cell involvement in tissue remodeling and repair following acute CNS injuries. Glia. 2014;62(11):1895–1904.
53. Bettinger I, Thanos S, Paulus W. Microglia promote glioma migration. Acta Neuropathol. 2002;103(4):351–355.
54. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437.
55. Kennedy BC, Showers CR, Anderson DE, et al. Tumor-associated macrophages in glioma: friend or foe? J Oncol. 2013;2013: 486912.
56. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A. 2000;97(23): 12846–12851.
57. of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 2002;62(24):7170–7174.
58. Widestrand A, Faijerson J, Wilhelmsson U, et al. Increased neurogenesis and astrogenesis from neural progenitor cells grafted in the hippocampus of GFAP-/- Vim-/- mice. Stem Cells. 2007;25(10):2619–2627.